{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:25:25Z","timestamp":1791487525812,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd006242","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T00:00:00Z","timestamp":1402531200000}}],"reference-count":65,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006242.pub2","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T01:02:58Z","timestamp":1402534978000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Trastuzumab-containing regimens for metastatic breast cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Sara","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mantarro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine; University of Pisa; Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology; University of Padova, Istituto Oncologico Veneto IRCCS; Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Tagliabue","sequence":"additional","affiliation":[{"name":"Medical Staff Directory; San Luca Hospital, Auxologic Institute; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Pistotti","sequence":"additional","affiliation":[{"name":"Cochrane Italy and IRCCS Mario Negri Institute for Pharmacological Research; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[{"name":"Cochrane Italy, Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"issue":"21","key":"10.1002\/14651858.CD006242.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006242.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"O'Shaughnessy J Blackwell KL Burstein H Storniolo AM Sledge G Baselga J A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [Abstract 1015] American Society of Clinical Oncology 2008","DOI":"10.1158\/0008-5472.SABCS-09-61"},{"issue":"12","key":"10.1002\/14651858.CD006242.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2582-90","DOI":"10.1093\/annonc\/mdr014","article-title":"Impact of lapatinib plus trastuzumab versus single agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer","volume":"22","author":"Wu","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0005|cit5","unstructured":"Gasparini G Gion M Crivellari D Morabito A Rocco S Spada A Interim analysis of a randomized phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients (pts) with HER-2\/neu positive metastatic breast cancer (MBC): Clinical and biological results [Abstract 138] American Society of Clinical Oncology 2003"},{"issue":"3","key":"10.1002\/14651858.CD006242.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-006-9306-9","article-title":"Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer","volume":"101","author":"Gasparini","year":"2007","journal-title":"Breast Cancer Research and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD006242.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","article-title":"Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial","volume":"21","author":"Huober","year":"2012","journal-title":"The Breast"},{"issue":"33","key":"10.1002\/14651858.CD006242.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Extra J Cognetti F Maraninchi D Snyder R Mauriac L Tubiana-Hulin M Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer [Abstract 555] American Society of Clinical Oncology 2005","DOI":"10.1200\/jco.2005.23.16_suppl.555"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0010|cit10","first-page":"Abstract 672","article-title":"Randomised phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer","volume":"1","author":"Extra","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"19","key":"10.1002\/14651858.CD006242.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"Abstract 1276","DOI":"10.1016\/S0959-8049(99)81692-X","article-title":"Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone","volume":"35","author":"Baselga","year":"1999","journal-title":"European Journal of Cancer"},{"issue":"11","key":"10.1002\/14651858.CD006242.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1772-7","DOI":"10.1093\/annonc\/mdi371","article-title":"Isolated central nervous system metastases in patients withHER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy","volume":"16","author":"Burstein","year":"2005","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006242.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/12.suppl_1.S57","article-title":"Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0015|cit15","unstructured":"Osoba D Burchmore M Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin) [Abstract] Seminars in Oncology 1999"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0016|cit16","unstructured":"Osoba D Slamon DJ Burchmore M Murphy M Effects of treatment with Her2mab (trastuzumab\/Herceptin\u2122) plus chemotherapy (H+C) versus chemotherapy alone (C) on health-related quality of life (HRQL) in women with HER-2\/neu-overexpressing metastatic breast cancer [Abstract 109] American Society of Clinical Oncology 2001"},{"issue":"14","key":"10.1002\/14651858.CD006242.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.2002.03.090","article-title":"Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer","volume":"20","author":"Osoba","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD006242.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006242.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3816\/CBC.2004.n.033","article-title":"Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer","volume":"5","author":"Tripathy","year":"2004","journal-title":"Clinical Breast Cancer"},{"issue":"6","key":"10.1002\/14651858.CD006242.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression","volume":"22","author":"Tripathy","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006242.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000175098","article-title":"Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression","volume":"3","author":"Pirvulescu","year":"2008","journal-title":"Breast Care"},{"issue":"12","key":"10.1002\/14651858.CD006242.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2008.19.6618","article-title":"Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26\/breast international group 03-05 study","volume":"27","author":"Minckwitz","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD006242.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.ejca.2011.06.021","article-title":"Trastuzumab beyond progression: overall survival analysis of the GBG 26\/BIG 3-05 phase III study in HER2-positive breast cancer","volume":"47","author":"Minckwitz","year":"2011","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"von Minckwitz G Zielinski C Maarteense E Vogel P Schmidt M Eidtmann H Capecitabine vs capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26\/BIG 3-05) [Abstract 1025] American Society of Clinical Oncology 2008","DOI":"10.1200\/jco.2008.26.15_suppl.1025"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0025|cit25","first-page":"Abstract LBA 67","article-title":"Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31\/GSK EGF 108919","volume":"30 Suppl","author":"Gelmon","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006242.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/annonc\/mdj110","article-title":"A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease","volume":"17","author":"Papaldo","year":"2006","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006242.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3816\/CBC.2004.n.005","article-title":"Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer","volume":"4","author":"Raff","year":"2004","journal-title":"Clinical Breast Cancer"},{"issue":"5","key":"10.1002\/14651858.CD006242.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","article-title":"Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures","volume":"93","author":"Apolone","year":"2005","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006242.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006242.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1634\/theoncologist.2013-0065","article-title":"Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study","volume":"18","author":"Bonifazi","year":"2013","journal-title":"The Oncologist"},{"issue":"11","key":"10.1002\/14651858.CD006242.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/annonc\/mdi371","article-title":"Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy","volume":"16","author":"Burstein","year":"2005","journal-title":"Annals of Oncology"},{"issue":"13","key":"10.1002\/14651858.CD006242.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","article-title":"Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial","volume":"14","author":"Buzdar","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"9","key":"10.1002\/14651858.CD006242.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"4730","key":"10.1002\/14651858.CD006242.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0035|cit35","unstructured":"D'Amico R Bonafede E Balduzzi S Longo G Guarneri V Piacentini F Unplanned crossover in randomized controlled trials: consequences for efficacy and safety outcomes Abstracts of the 19th Cochrane Colloquium; 2011 October 19-22; Madrid Chichester John Wiley & Sons 2011"},{"issue":"27","key":"10.1002\/14651858.CD006242.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD006242.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0038|cit38","unstructured":"U.S. Food and Drug Administration. FDA Oncology Tools Approval Summary for Trastuzumab for HERCEPTIN http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 5 Aug 2013)"},{"issue":"12","key":"10.1002\/14651858.CD006242.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2893-917","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"42","key":"10.1002\/14651858.CD006242.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15420","article-title":"Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2(HER2): a systematic review and economic analysis","volume":"15","author":"Fleeman","year":"2011","journal-title":"Health Technology Assessment NIHR HTA programme"},{"issue":"5","key":"10.1002\/14651858.CD006242.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"361-70","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nature Reviews Cancer"},{"issue":"16","key":"10.1002\/14651858.CD006242.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study","volume":"30","author":"Guarneri","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendation","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD006242.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdq593","article-title":"The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis","volume":"22","author":"Harris","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0045|cit45","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"c4875","DOI":"10.1136\/bmj.c4875","article-title":"The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence","volume":"341","author":"Ioannidis","year":"2010","journal-title":"BMJ"},{"issue":"7521","key":"10.1002\/14651858.CD006242.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/bmj.331.7521.895","article-title":"Disappointing biotech","volume":"331","author":"Joppi","year":"2005","journal-title":"BMJ"},{"issue":"20","key":"10.1002\/14651858.CD006242.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006242.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1524-4741.2010.01034.x","article-title":"A meta-analysis of randomised controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer","volume":"17","author":"Liao","year":"2011","journal-title":"The Breast Journal"},{"issue":"3","key":"10.1002\/14651858.CD006242.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/030089161009600302","article-title":"Use of trastuzumab in HER2-positive metastatic breast cancer beyond progression: a systematic review of published studies","volume":"96","author":"Mannocci","year":"2010","journal-title":"Tumori"},{"issue":"24","key":"10.1002\/14651858.CD006242.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/jnci\/djn414","article-title":"Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer","volume":"100","author":"Mauri","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"26","key":"10.1002\/14651858.CD006242.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006242.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0054|cit54","unstructured":"National Institute for Health and Care Excellence Breast cancer - trastuzumab [TA 34] London: National Institute for Health and Care Excellence (http:\/\/www.nice.org.uk\/page.aspx?o=29274) (accessed 9 February 2006)"},{"issue":"24","key":"10.1002\/14651858.CD006242.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006242.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdl064","article-title":"Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)","volume":"17","author":"Pestalozzi","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"9","author":"Schneeweiss","year":"2013","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006242.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0060|cit60","volume-title":"Experimental and Quasi-experimental Designs for Generalized Causal Inference","author":"Shadish","year":"2002"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/oxfordjournals.jncimonographs.a003453","article-title":"Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?","volume":"30","author":"Simes","year":"2001","journal-title":"Journal of the National Cancer Institute. Monographs"},{"issue":"4785","key":"10.1002\/14651858.CD006242.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"11","key":"10.1002\/14651858.CD006242.pub2-BIB0063|cit63","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: an overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD006242.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000055400","article-title":"First-line Herceptin monotherapy in metastatic breast cancer","volume":"61 Suppl 2","author":"Vogel","year":"2001","journal-title":"Oncology"},{"issue":"7","key":"10.1002\/14651858.CD006242.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008941.pub2","article-title":"Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer","author":"Wagner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006242.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T03:47:37Z","timestamp":1636602457000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006242.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Breast Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006242.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]}}}